rs671 is a genetic variant on gene ALDH2 associated with Chronic obstructive pulmonary disease and Coronary artery disease.
This variant is located on chromosome 12. The variations at position 111803962 are the genetic letters A/A, G/G, A/G
Since humans have each twice (one from each parent), these letter-variations occur on both chromosomes. People can have the same or different letters on both chromosomes. Every person's individual variation combination is referred to as genotype. For variant rs671 there are 3 currently known genotypes : A/A, G/G or A/G
rs671 is located on gene ALDH2 in chromsome 12. Use the genome browser to explore the location of rs671 and its genetic neighbourhood.
rs671 affects the following conditions and traits:
rs671 affects the following conditions:
rs671 is commonly tested together with other variants on the same gene.
This interactive browser visualizes what no human can see with the naked eye - our DNA. From a down to a specific position on a . The position you are looking at here is the exact location of variant rs on gene ALDH2. Explore more variants and their effects on the body by browsing left and right along the DNA strand.
Mutations are random changes in the DNA and genetic variations are differences in the DNA among people. Variants are tiny changes in just one piece of the DNA while haplotypes are groups of these changes that usually come together.
Dr. Wallerstorfer
The different genotypes of variant rs671 can affect the expression or likelyhood of developing certain traits or conditions. Current research shows that 8 conditions and 0 traits are associated with rs671. The following table shows the relationship between genotypes and conditions and traits.
Genetic variants can influence how our body reacts to certain drugs. The presence of specific genetic variants can increase or decrease the efficiency and effectiveness of a drug, impacting how well it works inside our system. Additionally, certain genetic variants can heighten or lessen the toxicity of a drug, thereby affecting the risk of unwanted side effects. They can also alter how a drug is metabolized, which influences the appropriate dosage one should receive.
Dr. Wallerstorfer
Clinical testing classifications are designed to help doctors understand how genetic changes, known as variants, might affect a person’s health and guide medical decisions. Variants are labeled as Disease Causing (harmful), likely Disease Causing, Unknown Effect (unknown impact), Likely No Effect (likely not harmful), and No Effect (not harmful). This classification relies on a mix of family history, lab tests, and computer predictions to determine the impact of variants.
Variants can have different effects based on their location. Variants on the X chromosome often impact males more because they have only one X chromosome, while females have two. This influences the classification (effect) of the variant.
Clinical Testing
Scientific Studies
Biological Male Symbol
Biological Female Symbol
Unisex Symbol for both Genders
Genotype
A
A
Level of evidence
Unknown effect
Unisex
1 Sources
Participants: 0
The genotype with the letters A/A has an unknown effect on your disease risk. This means that the scientific evidence is still somewhat unclear about its effect.
Genotype
G
G
Level of evidence
No Effect
Unisex
1 Sources
Participants: 0
The genotype with the letters G/G is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Genotype
A
G
Level of evidence
Unknown effect
Unisex
1 Sources
Participants: 0
The genotype with the letters A/G has an unknown effect on your disease risk. This means that the scientific evidence is still somewhat unclear about its effect.
Genotype
A
A
Level of evidence
Unknown effect
Unisex
1 Sources
Participants: 0
The genotype with the letters A/A has an unknown effect on your disease risk. This means that the scientific evidence is still somewhat unclear about its effect.
Genotype
G
G
Level of evidence
No Effect
Unisex
1 Sources
Participants: 0
The genotype with the letters G/G is thought to have no effect on your disease risk. Carriers of this genetic result are usually not at risk of developing the disease.
Genotype
A
G
Level of evidence
Unknown effect
Unisex
1 Sources
Participants: 0
The genotype with the letters A/G has an unknown effect on your disease risk. This means that the scientific evidence is still somewhat unclear about its effect.
Scientific studies classifications aim to uncover how genetic variants function and their roles in diseases, traits, and evolution. Variants are categorized based on their functional impact, such as loss-of-function (reduces gene activity), gain-of-function (increases gene activity), neutral (no significant impact), or evolutionary conservation. This classification uses experimental data, population studies, and computational analyses to understand variant effects. Unlike clinical testing, which focuses on immediate health impacts, scientific studies explore broader genetic mechanisms and long-term implications.
Genotype
A
A
Level of evidence
No Effect
Unisex
1 Sources
Participants: 635145
No available data
Genotype
A
G
Level of evidence
No Effect
Unisex
1 Sources
Participants: 635145
No available data
Genotype
A
A
Level of evidence
No Effect
Unisex
1 Sources
Participants: 635145
No available data
Genotype
A
G
Level of evidence
No Effect
Unisex
1 Sources
Participants: 635145
No available data
The genetic variant rs671 impacts how certain medications work in the body. This difference may cause some of us to require different dosage amounts to achieve the desired effects, while others might experience more apparent side-effects. As a result, healthcare providers may need to adjust prescriptions for those individuals with rs671. Ultimately, understanding our genetic makeup helps improve the overall effectiveness and usability of medications. Tailoring treatments based on genetics ensures a safer, more personalized healthcare experience.
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype A/A have decreased Drug Effect to NALTREXONE.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype A/G have increased Drug Effect to NALTREXONE.
more info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype G/G have increased Drug Effect to NALTREXONE.
more info
Legend:
Increased
Decreased
No known effect
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype A/A have decreased Drug Effect to NALTREXONE.
More info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype A/G have increased Drug Effect to NALTREXONE.
More info
Breakdown
Drug Effect
Side Effects
Dosage
Individuals with the genotype G/G have increased Drug Effect to NALTREXONE.
More info
Legend:
Increased
Decreased
No known effect
rs671 is commonly tested together with other variants on the same gene.
Conditions and traits are often affected by more than one variant. It is important to understand these other factors to get a better understanding of how genetics affect certain conditions and traits. The following grid shows other variants that affect the same conditions and traits as rs671.
Knowing your genome can actually tell you a lot about your ancestors.
The prevalence of the different genotypes is based on the native inhabitants of a region. In the map below you see how common each genotype is in the native inhabitants of those regions. Since genetic material is passed down form generation to generation, your DNA shows traces of the geographical origins of your ancestors.
This data is based on “The 1000 Genomes Project” which established one of the most detailed overviews of human genetic variations across the globe. The regions are broadly categorized into five continental groups: Africa, America, Europe, South Asia and East Asia. All continental groups together display the global prevalence. Click through the regions, to learn more about the local prevalence of the possible genotypes.
At present, there is no distribution data available for SNP 671. 671.
All of the resources below examine variant rs
James J. Gilchrist, Kathryn Auckland, Tom Parks, Alexander J. Mentzer, Lily Goldblatt, Vivek Naranbhai, Gavin Band, Kirk A. Rockett, Ousmane B. Toure, Salimata Konate, Sibiri Sissoko, Abdoulaye A. Djimdé, Mahamadou A. Thera, Ogobara K. Doumbo, Samba Sow, Sian Floyd, Jörg M. Pönnighaus, David K. Warndorff, Amelia C. Crampin, Paul E. M. Fine, Benjamin P. Fairfax, Adrian V. S. Hill, Alexander E. Gorbalenya, Erwin Schurr, Alexander E. Gorbalenya, Erwin Schurr, Alexander E. Gorbalenya, Erwin Schurr
Yuan-Bin Liu, Ming-Kai Chen
Junye Ge, Wenqiang Han, Chuanzhen Ma, Tongshuai Chen, Huiyu Liu, Kellina Maduray, Yinan Qu, Yihan Li, Tong Hu, Qinhong Wang, Jingquan Zhong